TIDES Asia is the ONLY event in Asia to bring oligonucleotide, peptide, mRNA, genome editing and drug delivery experts together in one forum to share drug discovery to manufacturing strategies to accelerate these drug modalities to market. 🧪 With 250+ attendees expected, expand your Asia network and register your pass before January 24 to save $300! 👇 https://lnkd.in/dGuQ_RB
TIDES: Oligonucleotides and Peptide Therapeutics
Events Services
Industry's largest & most renowned event series to accelerate your oligonucleotide and peptide therapeutics to market.
About us
TIDES is the industry's premier event series focused on accelerating oligonucleotide and peptide therapeutics to market. Our offerings include: Cutting-edge hybrid conferences and exhibitions Insightful digital webinars Authoritative publications Tailored networking opportunities Connecting researchers, developers, and industry leaders to drive breakthroughs in therapeutic development and commercialization.
- Website
-
https://informaconnect.com/tides-oligonucleotide-and-peptide-therapeutics-series/
External link for TIDES: Oligonucleotides and Peptide Therapeutics
- Industry
- Events Services
- Company size
- 2-10 employees
- Specialties
- Oligonucleotides, Peptides, mRNA, and Genome Editing
Updates
-
TIDES: Oligonucleotides and Peptide Therapeutics reposted this
🎵 On the twelfth day of the holidays, Professor Molenium gave to you: 🎵 👏 Twelve chemists clapping 💫 Eleven stir bars spinning ✨Ten glow sticks glowing 💥 Nine lasers shining ⚗️ Eight molecules vibrating 🌟 Seven x-rays scattering 🥂 Six champagnes fizzing 🐍 Five benzene rings 🔊 Four Tiny Matters 🧫 Three fermentations 🤓 Two season meetings 🎄 And a periodic table chemistree
-
-
Congratulations to the Tides Global team for a great year covering the latest in drug modality discovery. Here's to an even better 2025! Check out Søren Hough, PhD and Nnenna Ohaka's roundup below:
"Fanzor, LEGO, and protists – oh my! Tides Global’s favorite innovations of 2024" Nnenna Ohaka and I are excited to share our end-of-the-year roundup of the coolest innovations we've covered at Tides Global. There was so much more we could have included in this list, but hopefully this gives you a sense of the amazing developments going on in biomedical discovery. Thank you so much to Nnenna, Dan, and the whole editorial team – we couldn't have done this without your warm support. We can't wait to see what 2025 brings. To all of those celebrating, have a happy holiday season and a great new year! See you on the other side. https://lnkd.in/e_Qve_Wp
-
-
Søren Hough, Editor at Tides Global, has penned a new essay discussing the excitement and perils of CRISPR technology. Give it a read below, and be sure to sign up to our newsletter so you can be the first to read these articles when they go live: https://lnkd.in/enwQaFAK
I wouldn't have been able to complete my PhD research without CRISPR. I think it's one of the most incredible tools in the history of the field of biology. But with great power, as they say, comes great responsibility. My Letter from the Editor discusses the perils of medical racism and ableism, and how these histories must be considered as CRISPR use in humans - particularly heritable genome editing - inches closer to reality. https://lnkd.in/eDsRG-mu (I believe these points have particular salience as we find ourselves in UK Disability History Month.) Depicted below: Prometheus giving fire to humanity, as depicted by Hugo Vogel (1910).
-
-
Check out the second part of last week's story on a novel Parkinson's disease peptide therapeutic over at Tides Global!
Last week, I shared a story about preclinical research into a peptide treatment for Parkinson's disease. In my follow-up, I look at the ongoing clinical studies being conducted with this drug candidate and discuss with leading Parkinson's experts about how it could change the game for patients: https://lnkd.in/eEaf7quJ
-
-
Researchers are coming up with innovative ways to get massive genes into the right cells – this time, ribozymes come to the rescue. Check out the latest from Nnenna Ohaka at Tides Global below.
An RNA-based technology, StitchR, could be the key to developing effective gene therapies for muscular dystrophies. Read more on Tides Global: https://lnkd.in/e2MmpYBi
-
-
🚨 TIDES Europe 2024: How Industry Leaders Made an Impact 🚨 This year’s event brought together 700+ attendees, 90+ exhibitors, and 120+ speakers to drive innovation and collaboration in oligonucleotide, peptide, and mRNA therapeutics. A huge shoutout to our amazing sponsors—Codexis, Inc., ST PHARM, BioSpring GmbH, PolyPeptide Group, WuXi AppTec/WuXi Chemistry, and many more—for showcasing cutting-edge solutions and making a real impact. 🎥 Don’t just take our word for it! Hear the success stories from our sponsors & exhibitors: DuPont, ChemGenes, TriLink BioTechnologies, part of Maravai LifeSciences and Fluid Air. 📩 Let’s talk sponsorship opportunities for 2025! https://lnkd.in/e9AzY63Y #TIDES2024 #TIDES2025 #SponsorshipOpportunities #BiotechInnovation
-
Check out this dispatch from TIDES Europe 2024, as reported on by Tides Global. Remember, Part 2 releases next week!
Parkinson's disease is a terminal illness that affects ten million people worldwide. Despite this, current medication options largely treat symptoms and mask the underlying neurodegeneration. Now, a new disease-modifying peptide called HER-096 may halt Parkinson's progression — at least, if animal models are anything to go by. Check out my full report below: https://lnkd.in/eKbXr-ye And stay tuned next week for the final installment in this two-part series where we explore early clinical data for this peptide.
-
-
TIDES: Oligonucleotides and Peptide Therapeutics reposted this
Multiple production lines, low bioburden control, and a solvent regeneration policy formed part of Novartis’s considerations when developing an inhouse oligonucleotide strategy. TIDES: Oligonucleotides and Peptide Therapeutics Europe #TidesGlobal
-
Of all of the ways bacteria have evolved to evade antibiotics, shapeshifting ribosomal RNA has got to be one of the most fascinating. Check out the full Tides Global article below, and be sure to sign up to our newsletter to have stories like this delivered straight to your inbox: https://lnkd.in/enwQaFAK
Scientists at the Centre for Genomic Regulation (CGR) in Barcelona, Spain, have identified bacteria’s latest strategy for maintaining antibiotic resistance: altering ribosomal RNA (rRNA). Read more: https://lnkd.in/eHkHnJcZ
-